PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|23|39|6033-6041

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.39, 2018-02, pp. : 6033-6041

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B

By Chen Ji   Wang Xiao-Mei   Wu Xue-Jie   Wang Yan   Zhao Hong   Shen Bing   Wang Gui-Qiang  

Inflammation Research, Vol. 60, Iss. 1, 2011-01 ,pp. : 47-53

Springer Publishing Company

Access to resources Recommend Favorite

IO Nation: The Rise of Immuno-Oncology

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 12, Iss. 3, 2015-03 ,pp. : 176-181

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecules as Potent Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors Documented in Patents from 2009 to 2013

By  

Mini Reviews in Medicinal Chemistry, Vol. 15, Iss. 2, 2015-03 ,pp. : 104-122

Bentham Science Publishers

Access to resources Recommend Favorite

PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders

By  

Current Drug Delivery, Vol. 14, Iss. 6, 2017-09 ,pp. : 791-796

Bentham Science Publishers

Access to resources Recommend Favorite

PD-1 Signaling in HIV and Chronic Viral Infection - Potential for Therapeutic Intervention?

By  

Current Medicinal Chemistry, Vol. 18, Iss. 26, 2011-09 ,pp. : 3971-3980

Bentham Science Publishers

Access to resources Recommend Favorite